Harnessing the brain’s immune system to fight neurodegeneration
CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.Read More
CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI).
CSP-1103 is a novel, first class, small molecule microglial modulator that protects neurons and other cells in the brain.Read More
- CereSpir Incorporated Obtains New Patent from USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease
- CereSpir Incorporated Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer’s Disease
- CereSpir Incorporation Appoints Sophie Egholm as Chief Operating Officer